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ABSTRACT 
Despite effective treatment for chronic hepatitis C (CHC), deficiencies in diagnosis and access 
preclude disease elimination. Screening of baby boomers remains low. The aims of this study 
were to assess the impact of an electronic health record (EHR) based prompt on HCV 
screening rates in baby boomers in primary care, and access to specialty care and treatment 
among those newly diagnosed. We implemented an EHR based “Best Practice Advisory” (BPA) 
that prompted primary care providers (PCPs) to perform HCV screening for patients seen in 
primary care clinic: 1) born between 1945-1965; 2) lacked a prior diagnosis of HCV infection; 
and 3) lacked prior documented anti-HCV testing. The BPA had associated educational 
materials, order set, and streamlined access to specialty care for newly diagnosed patients. Pre 
and post BPA screening rates were compared and care of newly diagnosed patients analyzed. 
In the 3 years prior to BPA implementation, 52,660 baby boomers were seen in primary care 
clinics, and 28% were screened. HCV screening increased from 7.6% for patients with a PCP 
visit in the 6 months prior to BPA to 72% over the 1-year post BPA.  Of 53 newly diagnosed 
patients, all were referred for specialty care, 11 had advanced fibrosis or cirrhosis, 20 started 
treatment and 9 achieved SVR thus far. Conclusions: Implementation of an EHR based prompt 
increased HCV screening rates among baby boomers in primary care by 5 fold due to efficiency 
in determining needs for HCV screening and work-flow design. Streamlined access to specialty 
care enabled patients with previously undiagnosed advanced disease to be cured. This 
intervention can be easily integrated into EHR systems to increase HCV diagnosis and linkage 
to care. 
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INTRODUCTION 
Over the last few years there have been revolutionary advances in the treatment of chronic 
hepatitis C (CHC). Current treatments with direct-acting antiviral agents (DAAs) are highly 
efficacious with sustained virologic response (SVR) rates of >95% for the vast majority of 
patients.(1, 2) Moreover, unlike interferon-based therapies, DAAs are administered orally, have 
minimal side effects, and are of short duration. Thus, almost all CHC patients are candidates for 
treatment. Despite the dramatic advances in therapy, there remain significant barriers to 
hepatitis C virus (HCV) elimination, primary of which are deficiencies in screening and diagnosis 
of patients with CHC and subsequent linkage to care.(3) It has been estimated that only 50-65% 
of the estimated 3.2 million persons chronically infected with HCV in the United States are 
aware of their infection.(4-6) Given that risk based screening had not adequately addressed this 
deficiency, the Centers for Disease Control and Prevention (CDC) and the United States 
Preventive Services Task Force (USPSTF) recommended one-time screening for all baby 
boomers (adults born between 1945 and 1965) regardless of the presence of any of the 
traditional risk factors for HCV because this cohort has 5-fold higher prevalence of HCV than 
persons in other age groups.(7, 8) 
 
Despite this evidence-based recommendation, uptake of one-time universal HCV screening 
among baby boomers remains low. The reported ranges for screening among this cohort varies, 
but in general are estimated to be <30%, even after implementing interventions specifically 
aimed at increasing HCV screening among baby boomers.(9-12) Various approaches have 
been evaluated to optimize screening rates including integration of HCV screening into other 
preventive health screening like colonoscopy or HIV testing, as well as screening in emergency 
room and inpatient settings.(13-16) In order for HCV screening to have the highest impact 
however, screening needs to be linked with subsequent care after test results are available. 
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Prior estimates from outpatient and emergency room settings have shown that 30-50% of 
persons who test positive for HCV antibody (anti-HCV) never receive confirmatory HCV RNA 
testing, and among those with a confirmed diagnosis of HCV infection, only a minority 
(approximately 35%) are connected with specialty care.(17-19) As such, conducting HCV 
screening through an established primary care provider (PCP) has been hypothesized as 
having a higher likelihood of minimizing gaps in follow-up. These interventions need to be 
cognizant of minimizing work load and stretching the already overburdened PCPs. 
 
Given the almost universal use of electronic health record (EHR) systems, there has been much 
interest in methods to incorporate automatic prompts into EHRs as these represent a potentially 
efficient and effective approach to incorporate HCV screening within the context of a busy PCP 
clinic visit.(20) Integrating downstream work-flow to optimize referral and ultimately access to 
DAA therapy would further increase the overall impact of an HCV screening program and 
address critical deficiencies in the HCV “care cascade” where only 7.4% of diagnosed patients 
are estimated to have been started on HCV treatment globally.(21) We developed a Best 
Practice Advisory (BPA) in our EHR to prompt HCV screening among baby boomers and 
designed a detailed work-flow for subsequent care management for newly diagnosed patients. 
The primary aim of this study was to assess the impact of our EHR based prompt on HCV 
screening rates in baby boomers seen in primary care clinics.  Secondary aims included access 
to specialty care and curative treatment among patients newly diagnosed with CHC. 
 
METHODS 
Assessment of Pre and Post BPA Screening Rates 
In order to compare HCV screening rates and patient/provider characteristics associated with 
screening patterns, we evaluated all adult patients within the baby boomer cohort who had at 
least one visit during the prior 3 years, in primary care clinics in our health system which has 
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clinics in 13 locations within a 30-mile radius from our main campus in Ann Arbor. All providers 
are employed by the University of Michigan and all clinics use the same EHR system. Primary 
care clinics encompass 4 different medicine specialties: general internal medicine, family 
medicine, medicine/pediatrics, and geriatrics. We assessed rates of both anti-HCV orders and 
anti-HCV tests performed to capture potential discrepancies between screening orders and 
screening tests completed. We additionally assessed rates of anti-HCV positivity and 
downstream confirmatory HCV RNA testing and results. To examine association between 
patient and provider characteristics and screening patterns, we collected data on patient age, 
gender, race/ethnicity and insurance provider, as well as clinic sites and provider specialties. 
The baseline screening period consisted of the 3 years prior to implementation of the BPA.  The 
post BPA screening period consisted of 1-year post system wide implementation of the BPA. 
We assessed screening rates both by number of screening eligible PCP visits and by screening 
eligible patients (as patients had varying numbers of PCP clinic visits over the study periods of 
interest). This study was approved by the University of Michigan Institutional Review Board.   
Design of Best Practice Advisory: PCP Clinic Visit 
A BPA alert was developed in conjunction with our EHR Population and Health Management 
Ambulatory Care Services Team and consultation from several PCPs with the primary aim of 
increasing uptake of one-time HCV screening for baby boomers. As part of this initiative, patient 
educational flyers regarding rationale for HCV screening in baby boomers were posted in 
primary care clinics and educational materials were also provided in the electronic patient portal 
to raise awareness and prime patients for potential discussion about HCV screening during their 
visit.   The BPA would “fire” for any patient seen in primary care clinic that: 1) was born between 
1945-1965; 2) lacked a prior EHR ICD-9 or ICD-10 diagnosis code of HCV infection; and 3) 
lacked documented anti-HCV testing after 2009 in our EHR. A detailed illustration of the BPA 
Workflow is provided in Figure 1. To briefly review, upon rooming a patient for their 
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appointment, the medical assistant (MA) would inform the patient about age-based HCV 
screening and inquire if the patient had been screened elsewhere or prior to 2009 (which would 
not be captured in our EHR and thus the BPA would still fire if HCV screening was done 
externally or prior to 2009). If patient had anti-HCV testing performed prior to 2009 or 
elsewhere, the MA would override the BPA. If testing had not been performed prior, then the MA 
would provide patient educational materials on rationale for HCV screening, what the screening 
consisted of, and interpretation of test results. During the clinic visit, the PCP would then 
discuss HCV screening with the patient and indicate if the patient agreed with or declined 
testing. If “patient declines” was chosen as reason to not pursue testing, the BPA would fire 
again at the patient’s next visit after 10 months for all patients to allow PCPs to re-discuss HCV 
testing. Because some patients are seen at frequent intervals, the BPA did not fire at each 
subsequent visit. If the patient accepted screening, then a pre-populated “Smart Set” with anti-
HCV lab or er and associated diagnosis code would be signed. An illustration of the BPA 
interface is provided in Figure 2. Of note, this BPA was not designed as a “hard stop” in that the 
PCP could acknowledge the BPA but was not required to either document a reason for not 
testing or order testing in order for them to be able to continue to work in the patient’s 
encounter. This decision was made given that “hard stop” BPAs were in general poorly received 
by providers. 
Development of BPA: Follow-up on anti-HCV test results 
At the time of implementation of the BPA, our pathology lab did not have reflex testing in place 
for HCV RNA for samples that had reactive anti-HCV result due to concerns about potential 
contamination of previously used samples. Thus, patients with anti-HCV positive results were 
asked to return for HCV RNA testing. We developed result scripts to facilitate nurses’ (RN) 
follow-up with patients based on the result of their anti-HCV and HCV RNA tests.  Follow-up 
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work flow based on testing results is displayed in Figure 1. In addition, we provided guidelines 
on HCV consultations including recommended testing prior to referral. 
Design of BPA: Pilot testing 
The BPA was initially pilot-tested in three clinic sites (one general medicine, one family medicine 
and one medicine/pediatrics) over a 3-month period to ensure streamlined work-flow and to 
identify potential areas for improvement in implementation of the BPA. Feedback was solicited 
from patients, PCPs, RNs and MAs with regard to design and workflow. During the 3-month pilot 
phase, we identified the optimal timing for provision of the patient educational materials for HCV 
screening. Initially these materials were also made available prior to the appointment for eligible 
patients via the EHR patient portal, but this caused anxiety among a small number of patients 
and thus it was removed and provided during the clinic visit to allow PCPs to address 
questions/concerns in real time. During this pilot phase we also worked with our pathology 
department to improve the associated text that accompanied anti-HCV and HCV RNA test 
reports to simplify interpretation of results by both patients and providers.  We additionally 
engaged in conversation about the possibility of reflex testing for HCV RNA among patients with 
anti-HCV positive results. Lastly, we were able to assess logistics and demand for referral to 
specialty care. The BPA was then implemented across all primary care clinics.  
HCV Care Cascade  
In order to assess the downstream impact of our BPA, we followed the subsequent care 
cascade for all patients with a detectable HCV RNA. We assessed the number of patients 
referred to Hepatology clinic, number of patients seen, number of patients prescribed DAA 
therapy, number of patients started on DAA, and number of patients who achieved SVR 
(assessed at week 12 after completion of therapy). We also assessed stage of liver disease for 
the patients seen in Hepatology clinic. 
HCV Testing 
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Anti-HCV and HCV RNA tests were performed at the Clinical Pathology Laboratories at our 
main hospital for patients seen at all clinical sites. Anti-HCV was tested using a 
chemiluminescent immunoassay, Siemens ADVIA Centaur Immunoassay (Malvern, 
Pennsyvlania). A signal to cutoff ratio of 1-10.99 was categorized as weakly reactive and ≥11 
was categorized as reactive.  HCV RNA was tested using Abbott RealTime HCV Test (Abbott 
Park, Illinois) with a lower limit of detection of 12 international units/mL. 
Statistical Analyses 
Descriptive and bivariate analysis were performed to assess trends in testing and 
characteristics associated with screening. P values ≤0.05 were considered statistically 
significant. 
 
RESULTS 
Screening Rates and Characteristics in Pre and Post BPA Periods 
In the 3 year pre-BPA period, a total of 52,660 patients in the baby boomer cohort had a PCP 
visit. HCV screening was ordered in only 28% of patients over this 3-year period. HCV 
screening was more often performed in males (31% vs 26%), among African American and 
Asian patients (34% and 36% vs. 27-29%), and among patients with Medicaid or Medicare 
(34% and 32% vs 26-28%). Screening rates also varied substantially across clinic sites and 
clinic specialties as demonstrated in Table 1. The increase in screening rates and the 
associated patient and provider characteristics over the course of the post-BPA period are 
demonstrated in Table 1. Over the 1-year post BPA period, screening rates increased evenly 
across patient and provider characteristics, although screening rates within the single geriatrics 
clinic remained comparatively lower than other clinics.  
Regarding utilization of the BPA, “patient declines” was documented as a reason to not pursue 
screening only 4% of the time. Similarly, medical co-morbidities and prior testing elsewhere 
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were infrequently documented as a reason why HCV screening was not pursued (1% each). 
There was no reason documented why HCV screening was not performed or the lab order not 
signed in the remaining cases. Review of baby boomer PCP clinic visits over the study period 
demonstrated that approximately 31% of baby boomers seen in primary care clinics did not 
have the BPA fire due to prior HCV screening or pre-existing diagnosis of CHC. 
Diagnostic Testing Results in Pre and Post BPA Periods 
We compared HCV screening and diagnostic test results in a similar number of eligible clinic 
visits and eligible patients in the pre and post BPA period (Table 2). In the 6 month pre-BPA 
period, anti-HCV was ordered in only 4.6% of eligible visits and 7.6% of eligible patients 
compared to 47% and 72% in the 12 month post-BPA period (p= <0.001). When ordered, anti-
HCV test was performed in 99% of patients in both the pre and post BPA period. The rate of 
positive anti-HCV result was low in both the pre and post BPA periods (2% and 0.8% 
respectively). The frequency with which confirmatory HCV RNA test was ordered was higher in 
the post BPA period, though the difference was not statistically significant (86% vs 94%, 
p=0.09). It should be noted that reflex HCV RNA testing was implemented in June 2016 
(approximately the midpoint of our 1 year BPA implementation). 
The percentage of anti-HCV positive patients with a detectable HCV RNA was lower in the post 
BPA period (74% vs 33%, p <0.001).  Prior to implementation of reflex HCV RNA testing, anti-
HCV results were reported as reactive or weakly reactive based on the signal-to-cut-off ratio, 
whereas after reflex testing was implemented, anti-HCV results were reported only as reactive 
or non-reactive without further qualification (i.e. reactive vs weakly reactive). Eighty-three 
patients with a positive anti-HCV but undetectable HCV RNA had testing done prior to 
implementation of reflex HCV RNA testing. Of these, 69 (83%) were only weakly reactive on 
anti-HCV test. Among patients with a positive anti-HCV, those with undetectable HCV RNA 
were less likely to be African American (72% vs 85%, P=0.04), but had similar age distributions 
Page 10 of 23
Hepatology
Hepatology
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rt
ic
le
11 
 
(age 50-59 45% vs 34%, age 60-70 55% vs 66%, P=0.16) compared to those with detectable 
HCV RNA.  
HCV Care Cascade 
Among the 56 patients with an initial detectable HCV RNA in the post-BPA period, 3 patients 
had low HCV RNA levels (<12 international units/mL) that were not confirmed on subsequent 
testing. All 53 patients with confirmed CHC were referred to specialty care. At the time of data 
analysis, a total of 46 had attended their specialty clinic appointment, 1 had an upcoming 
appointment, 2 declined referral, and 4 were no longer seen at our center. Among these 53 
patients, 6 had cirrhosis by imaging or transient elastography, 3 had advanced fibrosis and 21 
had no or mild fibrosis (F0-F2) by transient elastography. Of the remaining 23 patients, 2 had 
aspartate aminotransferase to platelet ratio index (APRI) >1.5. Thus, in total, 11 of 53 (20.7%) 
patients with CHC had advanced fibrosis or cirrhosis.  
At the time of writing, DAA therapy was prescribed in 31 patients of whom 20 had started 
treatment. For the 11 prescribed DAA but not started on treatment, 6 were still pending approval 
of their DAA prescription, 4 were denied access to treatment by their insurance provider, and 
one patient was managed at an outside facility and thus treatment status was unknown. For the 
20 patients who started therapy, 9 had completed treatment and achieved SVR 12, and 11 
patients had SVR labs upcoming with 9 having end of treatment response (the remaining 2 
patients were still on therapy). (Figure 3) Of the 15 patients not yet prescribed DAA treatment, 7 
patients required additional follow-up assessment, 4 required management of severe active 
alcohol or substance abuse, 2 had active malignancies (one non-hepatic and one newly 
diagnosed HCC), 1 did not return for follow-up, and 1 was managed by another specialist 
outside our system.  
DISCUSSION 
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Despite revolutionary advances in treatment for CHC, HCV infection remains a worldwide public 
health problem due to the multiple systematic barriers to disease eradication. Given the 
potential morbidity and mortality resulting from CHC, interventions aimed at mitigating these 
deficiencies in the HCV care cascade are critical. The National Academies of Sciences, 
Engineering and Medicine recently released a report regarding a strategy to eliminate CHC with 
a goal to reduce new cases of HCV infection by 90% and mortality from CHC by 65% in the 
United States by the year 2030.(6) Key areas within this strategy focus on improvements in 
screening and diagnosis as well as improvement in access to specialty care and curative 
therapies. While various approaches have been evaluated to improve HCV screening across 
diverse patient care settings, most programs have resulted in only modest improvement in 
screening rates. Moreover, without linkage to subsequent confirmatory diagnostic testing and 
follow-up care, the impact of screening programs has been significantly muted. Herein we 
describe a low cost, efficient and highly effective EHR based HCV screening program for baby 
boomers in the primary care setting that resulted in a 5-fold increase in screening rates with 
subsequent successful linkage to specialty care and curative treatment.  
The findings of our study echoed those of prior investigations demonstrating the low rate of 
uptake of the universal recommendation for one-time HCV screening for baby boomers with 
only 28% of patients having been screened over the 3-year baseline assessment period. Also of 
note, the practice patterns at baseline varied according to gender, race, insurance type and 
clinic type. These discrepant screening rates have been shown previously and in part reflect 
perceived varying prevalence rates of HCV infection among different patient cohorts.(22) Of 
note, these practice variations disappeared once the BPA implementation had been in place for 
1 year, with screening rates being driven by baby boomer status and not by other demographic, 
insurance, or practice setting variables. HCV screening rates among baby boomers increased 
5-fold to 72% during the 1-year period after implementation of the EHR-based BPA. This HCV 
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screening rate among baby boomers is one of the highest cited in the literature to date. The 
success of this screening intervention is a direct result of the ease of the EHR design that was 
constructed based on the needs of and feedback provided by PCPs. Specifically, this BPA 
eliminated the burden of work previously placed on PCPs to first remember the need for HCV 
screening in this population and secondly to verify prior HCV testing or diagnosis of individual 
patients. There has been concern about “alert fatigue”, particularly on the part of PCPs who are 
asked to screen for numerous conditions within time constrained visits. Keeping this concern in 
mind, we developed the alert with input from a PCP (HC), did a pilot run for 3 months, and 
proactively solicited feedback from PCPs. We elected to not make the alert a “hard stop” for the 
clinic encounters and also decided to not have the BPA fire at each subsequent visit until it was 
addressed based on PCP feedback and in order to prevent impeding workflow.  As such, this 
BPA was favorably received by PCPs. Lastly, we incorporated educational materials for both 
patients and the medical staff in order to help decrease anxiety related to screening, reduce 
work load for PCP clinics, and to make it easy for staff to provide rationale for screening and 
explanation of subsequent results.   
 
In addition to the improvement in HCV screening were the associated improvements in 
confirmatory testing and subsequent linkage to care. Post-BPA, 94% of patients with a positive 
anti-HCV had a confirmatory HCV RNA ordered compared to only 86% in the pre-BPA period 
although these differences were not statistically significant and implementation of reflex HCV 
RNA testing during the latter part of the study period may also have contributed to this increase. 
Our rate of confirmatory testing compares favorably with estimates of only 30-50% in other 
studies.(17, 18)  Some studies showed that reflex HCV RNA testing can improve the likelihood 
of confirmatory testing and would certainly minimize inconvenience to patients and decrease 
their anxiety while waiting for additional testing. We are pleased that with continued dialogue 
with our pathology colleagues, we were able to incorporate reflex testing for HCV RNA in 
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patients who test positive for anti-HCV. Interestingly, in our cohort the prevalence of positive 
anti-HCV was low (2% and 0.8% in pre and post BPA period respectively). Estimates from the 
CDC for the baby boomer cohort cite an approximate 3.25% prevalence of anti-HCV, though 
similar studies have found lower rates when screening programs have been implemented for 
this population in non-urban primary care settings.(23-25) Our low anti-HCV positivity rate may 
also be reflective of the demographics of our patient population. In addition, many of our 
patients have been in our health system for many years and an estimated 31% of our baby 
boomers seen in primary care clinics did not have the BPA fire due to prior HCV screening or 
pre-existing diagnosis of CHC. Another interesting finding was the low rate of detectable HCV 
RNA in the post BPA period with only 33% of patients with positive anti-HCV having a 
detectable HCV RNA. Reviewing these cases in detail revealed that the majority of the patients 
who were anti-HCV positive but had undetectable HCV RNA had weakly reactive anti-HCV and 
thus were likely false positives. Similar findings had been observed in other studies when 
screening is conducted in larger numbers of persons with low risk of infection.(24, 26)  
Contrary to other studies of birth cohort screening, we had much higher success rates with 
follow-up care and subsequent DAA treatment. Within 6 months of the end of the 1-year post-
BPA implementation period, 100% of patients with newly diagnosed CHC were referred to 
specialty care with 87% already seen by a specialist and 67% of these patients prescribed DAA 
therapy. This success in bridging gaps in linkage to care after initial screening and diagnosis are 
reflective of the primary care based setting for the intervention that is more amenable to 
facilitating necessary follow-up. Data examining subsequent linkage to care and curative 
treatment from other similar EHR based interventions for HCV screening of baby boomers in 
primary care are limited. Our rates of visits with HCV specialists and initiation on DAA therapy 
were higher than other studies: 77% newly diagnosed patients seen by specialists in the study 
by Goel et al and 21% and 57% of newly diagnosed patients started on DAA in the studies by 
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Mera et al and Miller et al, respectively. (11, 27, 28) While most of the newly diagnosed patients 
had early stage disease, 20.7% had evidence of either cirrhosis or advanced fibrosis at the time 
of initial referral. These patients likely would remain undiagnosed until they present with 
decompensated liver disease, had they not been screened as a result of the BPA. With the high 
rate of cure in the DAA era, early diagnosis and treatment would prevent progression of liver 
disease. Though preliminary, our study showed that 9 of 9 evaluable patients achieved SVR 12 
and an additional 9 patients had end of treatment response.  
There are several limitations to our study. These include the relatively homogenous patient 
population with potentially lower risk of HCV infection that may have accounted for the low anti-
HCV positivity rate in this study. Secondly, while EHR has been adopted widely for clinical 
patient care, it may not be present in all settings and thus the applicability of this intervention 
would be limited to practices with EHR in place. Our hospital system uses an EPIC-based EHR 
which is used by many other health centers in the United States. The BPA design could easily 
be implemented in other EPIC based systems or adapted for other EHRs.  
In conclusion, we demonstrated that implementation of an EHR based BPA for HCV screening 
among baby boomers in the primary care setting resulted in a 5-fold increase in screening rates 
and was well received by PCPs. The associated structured work-flow to address confirmatory 
testing and referral to specialty care was critical in minimizing gaps in the HCV care cascade. 
As a result of this intervention, we were able to identify patients with CHC who likely would not 
be diagnosed and treated until they present with cirrhosis complications. This type of EHR 
based intervention represents a low cost, efficient and effective means to improve HCV 
screening, diagnosis and access to care which ultimately can lead to mitigation of the 
associated morbidity and mortality of CHC.  
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FIGURE LEGENDS 
Figure 1. HCV BPA Workflow HCV, hepatitis C virus; BPA, best practice advisory; PCP, primary care 
provider; MA, medical assistant; RN, registered nurse; CHC, chronic hepatitis C 
Figure 2. HCV BPA Design HCV, hepatitis C virus; BPA, best practice advisory 
Figure 3. HCV Care Cascade HCV, hepatitis C virus; DAA, direct acting anti-viral agent; EOT, end of 
treatment. Percentage outside of bar shows proportion accounting for only the number of patients 
eligible for that outcome. 
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Table 1: Screening Rates for Baby Boomers followed in Primary Care Pre and Post BPA* 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Represents all baby boomers considered active within UMHS primary care 
 (having had a PCP visit within 3 years prior to BPA and within the 1 year post- 
BPA time frame). Data expressed as % unless otherwise noted. 
^only one Med-Peds Clinic and one Geriatrics Clinic 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variable of Interest 
 
Screening Rates  
Pre-BPA 
 (N=52,660) 
Screening Rates 
Post BPA 
(N=52,832) 
Anti-HCV ordered 28 (14,870) 71 (37,459) 
Gender 
   Female 
   Male 
 
26 
31 
P=<0.001 
 
71 
71 
Age 
   50-59 
   60-70 
 
28.5  
28.5 
 
69 
73  
Race/Ethnicity 
     Caucasian 
     African American 
     Asian 
     Other/unknown 
 
 
27 
34 
36 
29 
P=<0.001 
 
72 
75 
77 
71 
Insurance 
   Commercial 
   Medicaid 
   Medicare 
 
                 
27 
34 
32 
P=<0.001 
 
70 
72  
76 
Clinic Specialty 
Median (range) 
   Gen Med 
   Fam Med 
   Med-Peds^ 
   Geriatrics^ 
 
Range: 19-34% 
32 (20-34) 
28 (20-32) 
25 
19 
P=<0.001 
 
Range: 50-78% 
73 (54-81) 
73(67-75) 
75 
50 
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Table 2: Screening and Diagnostic Testing in Pre and Post BPA Periods* 
Screening: Eligible Visits Pre-BPA  
N=37,289 
Post-BPA 
N=42,721 
Anti-HCV ordered 4.6% (1,716) 47% (19,895) 
 Anti-HCV drawn after order 99% (1,705) 99% (19,847) 
Screening: Eligible Patients Pre-BPA 
N=22,488 
Post-BPA  
N=27,789 
Anti-HCV ordered 7.6% (1,716) 72% (19,895) 
P=<0.001 
Anti-HCV drawn after order 99% (1,705) 99% (19,847) 
Positive Anti-HCV test  2.1% (36) 0.8% (178) 
Confirmatory Testing Pre-BPA 
N=36 
Post-BPA  
N=178 
HCV RNA ordered 86% (31) 94% (168) 
P= 0.09 
Detectable HCV RNA 74% (23) 33% (56) 
P=<0.001 
*Pre and Post BPA periods represent similar number of screening eligible PCP visits  
and patients.  Pre-BPA era captured 6 months prior to BPA implementation. Post-BPA  
period captured 1 year most BPA implementation. 
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Figure 1. HCV BPA Workflow  
HCV, hepatitis C virus; BPA, best practice advisory; PCP, primary care provider; MA, medical assistant; RN, 
registered nurse; CHC, chronic hepatitis C  
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Figure 2. HCV BPA Design  
HCV, hepatitis C virus; BPA, best practice advisory  
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Figure 3. HCV Care Cascade  
HCV, hepatitis C virus; DAA, direct acting anti-viral agent; EOT, end of treatment. Percentage outside of bar 
shows proportion accounting for only the number of patients eligible for that outcome.  
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